Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325192 | 0.92 | NAAA (0.47) | NAAA | |
| SCHEMBL10681615 | 0.90 | NAAA (0.50) | NAAA | |
| SCHEMBL9319665 | 0.90 | NAAA (0.50) | NAAA | |
| SCHEMBL8151755 | 0.90 | NAAA (0.50) | NAAA | |
| SCHEMBL356946 | 0.83 | — | — | |
| SCHEMBL4719861 | 0.77 | HSP90AA1 (0.32) | — | |
| SCHEMBL3030404 | 0.74 | NAAA (0.48) | NAAA | |
| SCHEMBL29104167 | 0.74 | NAAA (0.48) | NAAA | |
| SCHEMBL20561036 | 0.74 | NAAA (0.44) | NAAA | |
| SCHEMBL8011559 | 0.74 | NAAA (0.44) | NAAAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330243-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-116635082-A | Combination of antibody-drug conjugate and ATR inhibitor | 阿斯利康(英国)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023126823-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-07-06 | — | — | WO | disclosed |
| EP-4171650-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | AstraZeneca UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260582-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND AURORA B INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021260579-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-9421213-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-08-23 | — | — | US | disclosed |
| US-20160074412-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-03-17 | — | — | US | disclosed |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-29 | — | — | US | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058781-A1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024721-A1 | HYDANTOIN DERIVATIVES UND DEREN VERWENDUNG ALS TACE INHIBITOREN | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1243580-A1 | HETEROCYCLIC IMINO COMPOUNDS AND FUNGICIDES AND INSECTICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nissan Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-5606078-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0678514-A1 | 3,5-Disubstituted tetrahydrofuran-2-ones | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212116-A1 | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horitcultural use | DDT, CBR3, CYP1B1 | NAAA 3349/4885HDAC8 1673/4885 |
| US-20150307534-A1 | CHEMICAL COMPOUNDS | ABL1, NQO1, NQO2 | NAAA 1841/4885HDAC8 1826/4885 |
| US-20160074412-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | NAAA 3741/4885HDAC8 3840/4885 |
| US-20230330243-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ATR, ERBB2, ATRIP | NAAA 1048/4885HDAC8 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.